Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) .

[1] It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA.

[2][5] Tamibarotene shows a similar side effect profile to Tretinoin, but exhibits lower clearance, resulting in improved dosing regiments.

Reaction of the diol (1) with hydrogen chloride affords the corresponding dichloro derivative (2).

Aluminum chloride mediated Friedel–Crafts alkylation of acetanilide with the dichloride affords the tetralin (3).